IGF-1 LR3 Results Timeline: What Studies Measured, and When

What a "results timeline" would require, and what exists

A results timeline normally comes from trials that measure the same outcome, in the same participants, at fixed intervals — week 2, week 4, month 3 — so that a reader can see when a measured change appeared and when it plateaued. For long R3 insulin-like growth factor-1 (IGF-1 LR3), the PubMed-indexed record does not contain that kind of human trial series. The studies that exist are preclinical and use different species, different routes of delivery and different outcome measures, which means their timepoints cannot be stacked into a single human-facing schedule. A 2026 review in Frontiers in Endocrinology examined performance-enhancing peptides that modulate the GH–IGF1 axis and framed the problem explicitly as a gap between clinical evidence and patient self-administration (PMID 42395176).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any question involving a medicine, a hormone axis, or a research compound. Nothing below describes an outcome a person should expect, because no study in the verified set measured outcomes in people over time. Readers looking for background on the molecule itself can see the IGF-1 LR3 overview.

Timepoints that were actually measured

Acute exposure: minutes-to-hours in fetal sheep

The shortest timeframe in the verified literature is an acute one. Researchers infused IGF-1 LR3 into fetal sheep and reported that glucose-stimulated insulin secretion was attenuated during the acute infusion, while that attenuation did not persist when islets were subsequently isolated and tested (PMID 37114757). The structure of that study is informative for anyone thinking about timelines: it contains two distinct measurement windows — one during exposure, one after the tissue was removed from the exposure — and the signal present in the first window was not present in the second (PMID 37114757). A change observed while a compound is circulating is not automatically a change that persists.

Repeated dosing: an intranasal mouse model

A 2025 study in the Journal of Alzheimer's Disease used intranasal long R3 IGF-1 in male 5XFAD mice and reported that the treatment promoted amyloid plaque remodeling in the cerebral cortex but failed to preserve cognitive function (PMID 39610283). This is the clearest example in the set of two outcomes moving in different directions within the same experiment: a structural endpoint changed, and a functional endpoint did not (PMID 39610283). The route was intranasal and the subjects were mice carrying a transgenic Alzheimer's model, neither of which maps onto systemic administration in an adult human.

Sustained local release: a rat nerve conduit

A 2025 study in the International Journal of Biological Macromolecules built a decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release, and evaluated it for rat sciatic nerve regeneration (PMID 41015370). Here the peptide was not injected systemically at all; it was embedded in an implanted scaffold designed to release it gradually at a surgical site (PMID 41015370). Regeneration studies of this type measure recovery over a postoperative follow-up period, but the delivery architecture — a local, device-bound release profile — is a different pharmacological situation from circulating peptide, and the study's timeline belongs to the device, not to the molecule in isolation.

Study-by-study summary table

Outcomes that were not measured

The question of "how long until results" usually refers to body composition, strength, recovery or visible change. None of the studies in this verified set measured those endpoints. The fetal sheep work measured insulin secretion (PMID 37114757); the mouse work measured amyloid pathology and cognition (PMID 39610283); the rat work measured peripheral nerve regeneration after implantation of a release scaffold (PMID 41015370). A review of GH–IGF1-axis performance peptides addressed the discrepancy between what has been studied clinically and what is self-administered outside of clinical settings (PMID 42395176). Where a claim about weeks-to-visible-change circulates informally, it is not traceable to these papers.

Why preclinical timepoints do not convert into human weeks

Three features of the verified record block any arithmetic conversion:

• Species and developmental stage differ. A fetal sheep with an immature endocrine pancreas is not a model of adult human metabolism, and the study's measured effect on insulin secretion occurred during acute infusion rather than after a course of treatment (PMID 37114757).
• Routes differ. One study used intranasal delivery into the central nervous system of transgenic mice (PMID 39610283); another used a locally implanted biomaterial conduit (PMID 41015370). Exposure profiles from these routes are not interchangeable with each other or with systemic dosing.
• Endpoints differ. Insulin secretion, plaque morphology and axonal regeneration do not share a common clock, so a timepoint from one experiment says nothing about when another endpoint would change (PMID 37114757, PMID 39610283).

Structural change versus functional change

One of the most transferable lessons from this literature concerns what counts as a result. In the 5XFAD mouse study, researchers reported that an imaging- and histology-level feature changed while the behavioural outcome did not improve (PMID 39610283). In the fetal sheep study, a physiological response measured during exposure was absent once the tissue was studied ex vivo (PMID 37114757). Both results illustrate that a measurable biological change at a given timepoint is not equivalent to a durable or functionally meaningful outcome, which is why trial design places so much weight on which endpoint is being tracked and for how long.

Adverse Events: What Studies Report

The verified set contains limited safety reporting, and it is preclinical. The most directly relevant physiological signal is metabolic: the study in fetal sheep reported attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion, with that attenuation not persisting in isolated islets (PMID 37114757). Because IGF-1 analogues interact with insulin signalling, glucose-related parameters are a recurring focus of research attention in this area. At the review level, the 2026 Frontiers in Endocrinology paper discussed peptides modulating the GH–IGF1 axis specifically in terms of the distance between clinical evidence and patient self-administration, a framing that treats unsupervised use as a safety question rather than a settled practice (PMID 42395176). The other two studies were designed around efficacy endpoints in animal models rather than systematic human safety monitoring (PMID 39610283, PMID 41015370).

Regulatory context

IGF-1 LR3 is not an approved medicine for human performance, body-composition or anti-ageing indications, and material offered for laboratory work is typically labelled research-use-only. Sport anti-doping frameworks treat IGF-1 analogues as prohibited substances. The 2026 review placed self-administration of GH–IGF1-axis peptides outside the boundary of established clinical evidence (PMID 42395176). This page does not provide legal advice.

How the evidence could be read

1. No human timeline exists in this literature set, so any week-by-week expectation would be an extrapolation rather than a finding (PMID 42395176).
2. The only acute-exposure data point in the set concerns insulin secretion in a fetal animal model, measured during infusion (PMID 37114757).
3. Repeated central delivery in a mouse model moved a pathological structural marker without preserving function (PMID 39610283).
4. Local, device-mediated controlled release in rats was evaluated for nerve regeneration rather than systemic effects (PMID 41015370).

Anyone weighing this information alongside a personal health question is in territory that belongs to a licensed clinician, who can interpret growth-factor biology against an individual's glucose regulation, cancer history and medication list.

References

• Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets (Journal of Developmental Origins of Health and Disease, 2023)
• Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration (International Journal of Biological Macromolecules, 2025)
• Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice (Journal of Alzheimer's Disease, 2025)
• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Frontiers in Endocrinology, 2026)